• Korean
  • Chinese
表紙
市場調査レポート - 206607

ジェネリックおよびバイオシミラー注射剤:ディベロッパーの潜在的機会

Injectable Generic and Biosimilar Drugs - Potential Opportunities for Developers

発行 Espicom Business Intelligence
出版日 ページ情報 英文 172 Pages
価格
ジェネリックおよびバイオシミラー注射剤:ディベロッパーの潜在的機会 Injectable Generic and Biosimilar Drugs - Potential Opportunities for Developers
出版日: 2013年12月17日 ページ情報: 英文 172 Pages
概要

ジェネリック注射剤市場は、主要企業が買収によってそのプレゼンスを高めているため、この数年間にわたって整理統合の時期に直面しています。しかし、バイオジェネリック注射剤への関心は既存のジェネリック医薬品企業だけに限らず、Pfizerなどの製薬大手も同様に市場へ関心を寄せています。世界の注射剤市場規模はおよそ1,440億米ドルですが、ジェネリック注射剤の市場額は約122億米ドルであり、次の10年間に主要市場では数多くの高価な注射剤が特許期限切れを迎える予定になっています。しかし、人気製品の多くは生物製剤であり、バイオシミラーの認可は数社に限られる見込みです。先進市場における規制認可の獲得は、化学的ジェネリック医薬品よりもバイオシミラーの方が複雑で、治験に費用がかかると見られています。これまで、欧州でバイオシミラーの規制認可を獲得しているのは一握りの企業です。

当レポートは、世界のジェネリックおよびバイオシミラー注射剤市場について調査分析し、特定の治療領域における主要35製品の詳細なレビューを提供しており、各製品の作用機序、市場認可、競合、特許および市場展望を、収益分析と5カ年予測を含めた図表とともに提供しており、主要企業のプロファイルを交え、概略以下の構成で提供しております。

序文

エグゼクティブサマリー

注射剤市場

  • 市場規模

  • ホルモン療法
  • 化学療法
  • 補助療法

糖尿病

  • Humulin (インスリン rDNA origin)
  • Humalog (インスリンリスプロ)
  • Lantus (インスリングラルギン)
  • Apidra (インスリングルリジン)
  • Levemir (インスリンデテミル)
  • NovoRapid & NovoMix (インスリンアスパルト)
  • バイオシミラーヒトインスリン

血液

  • Epogen/Eprex/Procrit(エポエチンα)
  • Aranesp(ダルベポエチンα)
  • Lovenox/Clexane(エノキサパリン)

免疫

  • 多発性硬化症
  • 関節リウマチ

感染症

  • Cubicin (ダプトマイシン)
  • Invanz (エルタペネム)
  • Tygacil (チゲサイクリン)
  • Synagis (パリビズマブ)
  • PegIntron (PEG-インターフェロンα-2b)
  • Pegasys (ペグ化-40K -インターフェロンα-2a)
  • バイオシミラーインターフェロンα

主要企業

  • ACTAVIS
  • AKORN
  • AMERICAN REGENT
  • AMPHASTAR PHARMACEUTICALS
  • APOTEX
  • AUROBINDO PHARMA
  • CLARIS LIFESCIENCES
  • DR REDDY'S LABORATORIES
  • FRESENIUS KABI
  • HIKMA PHARMACEUTICALS
  • HOSPIRA
  • MYLAN
  • SAGENT PHARMACEUTICALS
  • SANDOS
  • STRIDES ARCOLAB
  • SUN PHARMA
  • TEVA PHARMACEUTICAL INDUSTRIES
  • WOCKHARDT

付録:FDA ANDA承認

情報源

インデックス

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

The market for injectable generics has been through a period of consolidation over the last few years as the leading companies have increased their presence through acquisition. The major players include Hospira, Sandoz (Novartis), Hikma Pharmaceuticals, Fresenius Kabi and Teva Pharmaceutical Industries. But interest in generic injectables has not been limited to established generic companies, as pharmaceutical majors like Pfizer have also become attracted to the market.

This is hardly surprising with a global injectables market in the region of US$144 billion. While the lion's share remains with the innovative industry for the time being, the generic injectables market is worth around US$12.2 billion and numerous high value injectable products will face patent expiry in major markets over the next decade. But, many of the big sellers are biological products and biosimilar approvals will only be possible for a few companies. Gaining regulatory approval in developed markets will be far more complex for biosimilars than for chemical generics and will involve costly clinical trials. To date, only a handful of companies have gained regulatory approval for biosimilars in Europe, and the US is likely to remain elusive to all but a select few. Among these, as the only US-based company with approval for biosimilars in the EU, Hospira is well positioned to take advantage of the potential US market.

This report features in-depth reviews of 35 major products within specific therapy areas. Each product review examines mode of action, market approvals, competition, patents and market outlook, with tables and charts analysing revenue and including five-year forecasts and more (where available). In addition, the report analyses the major competitors such as Actavis, Frensenius Kabi, Hospira, Sandoz and more...

What this report covers:

  • Executive Summary
  • Injectable Drugs Market - Market Size and Opportunities
  • Cancer - Hormonal Therapies, Chemotherapy, Monoclonal Antibodies, Supportive Therapies
  • Diabetes
  • Haematology
  • Immunology - Multiple Sclerosis, Rheumatoid Arthritis
  • Infection
  • Major Competitors

The Injectable Generic and Biosimilar Drugs Report is the foolproof business resource for any industry executive that needs to fully understand the current products and major competitors of the injectable drugs market. The need for hard facts and statistics to back up everyday business decisions is essential and it is this report that can provide you with the answers.

Table of Contents

FOREWORD 1

EXECUTIVE SUMMARY 3

INJECTABLE DRUGS MARKET 4

  • Market Size 4
    • Generic and Biosimilar Opportunities 5

CANCER 8

  • HORMONAL THERAPIES 8
    • Faslodex (fulvestrant) 8
      • Mode of Action 8
      • Approvals 8
      • Lifecycle Development 8
      • Competition within the Marketplace 8
      • Patents 9
      • Market Outlook 9
      • Generic Company Activity 10
    • Zoladex (goserelin) 11
      • Mode of Action 11
      • Approvals 11
      • Competition within the Marketplace 11
        • Breast Cancer 11
        • Prostate Cancer 12
      • Patents 12
      • Market Outlook 12
      • Generic Company Activity 13
        • Europe 13
        • North America 14
  • CHEMOTHERAPY 15
    • Eloxatin (oxaliplatin) 15
      • Mode of Action 15
      • Approvals 15
      • Competition within the Marketplace 15
      • Patents 16
      • Market Outlook 16
      • Generic Company Activity 17
        • The '874 Patent Litigation: At Risk Launches and Subsequent Withdrawals 17
        • Europe 18
    • Taxotere (docetaxel) 19
    • Mode of Action 19
    • Approvals 19
    • Competition within the Marketplace 19
    • Patents 19
    • Market Outlook 20
    • Generic Company Activity 20
      • Europe 20
      • US 21
    • Abraxane (paclitaxel protein-bound particles for injectable suspension; albumin-bound) 22
      • Mode of Action 22
      • Approvals 22
      • Competition within the Marketplace 22
      • Patents 23
      • Market Outlook 23
      • Generic Company Activity 24
    • Alimta (pemetrexed) 25
      • Mode of Action 25
      • Approvals 25
      • Lifecycle Development 25
      • Competition within the Marketplace 25
      • Patents 26
      • Market Outlook 26
      • Generic Company Activity 27
    • Velcade (bortezomib) 28
      • Mode of Action 28
      • Approvals 28
      • Competition within the Marketplace 28
      • Patents 28
      • Market Outlook 29
      • Generic Company Activity 30
      • MONOCLONAL ANTIBODIES 32
    • Rituxan/MabThera (rituximab) 32
      • Mode of Action 32
      • Approvals 32
      • Competition within the Marketplace 32
      • Patents 33
      • Market Outlook 33
      • Biosimilar Rituximab 34
    • Herceptin (trastuzumab) 35
      • Mode of Action 35
      • Approvals 35
      • Competition within the Marketplace 35
      • Breast Cancer 35
      • Gastric Cancer 36
      • Patents 36
      • Market Outlook 36
      • Biosimilar Trastuzumab 37
    • Avastin (bevacizumab) 38
      • Mode of Action 38
      • Approvals 38
      • Competition within the Marketplace 39
      • Patents 39
      • Market Outlook 39
      • Biosimilar Bevacizumab 40
    • Erbitux (cetuximab) 41
      • Mode of Action 41
      • Approvals 41
      • Competition within the Marketplace 41
      • Patents 42
      • Market Outlook 42
      • Biosimilar Cetuximab 43
  • SUPPORTIVE THERAPIES 44
    • G-CSF 44
    • Neupogen (filgrastim) 45
      • Mode of Action 45
      • Approvals 45
      • Competition within the Marketplace 45
      • Patents 45
      • Market Outlook 46
      • Biosimilar Filgrastim 46
        • Europe 46
        • USA 47
        • Rest of the World 48
    • Neulasta (pegfilgrastim) 49
      • Mode of Action 49
      • Approvals 49
      • Competition within the Marketplace 49
      • Patents 50
      • Market Outlook 50
      • Biosimilar Pegfilgrastim 51

DIABETES 52

  • Humulin (insulin [rDNA origin]) 53
    • Mode of Action 53
    • Approvals 53
    • Competition within the Marketplace 53
    • Market Outlook 53
  • Humalog (insulin lispro) 55
    • Mode of Action 55
    • Approvals 55
    • Competition within the Marketplace 55
    • Patents 55
    • Market Outlook 55
  • Lantus (insulin glargine) 57
    • Mode of Action 57
    • Approvals 57
    • Competition within the Marketplace 57
    • Patents 57
    • Market Outlook 58
  • Apidra (insulin glulisine) 59
    • Mode of Action 59
    • Approvals 59
    • Competition within the Marketplace 59
    • Patents 59
    • Market Outlook 60
  • Levemir (insulin detemir) 61
    • Mode of Action 61
    • Approvals 61
    • Competition within the Marketplace 61
    • Patents 61
    • Market Outlook 62
  • NovoRapid & NovoMix (insulin aspart) 63
    • Mode of Action 63
    • Approvals 63
    • Competition within the Marketplace 63
    • Patents 63
    • Market Outlook 64
  • Biosimilar Human Insulin 65
    • Europe and USA 65
    • Rest of the World 66

HAEMATOLOGY 67

  • Epogen/Eprex/Procrit (epoetin alfa) 68
    • Mode of Action 68
    • Approvals 68
    • Competition within the Marketplace 68
    • Patents 68
    • Market Outlook 69
    • Biosimilar Epoetin 70
      • EU 70
      • US 70
  • Aranesp (darbepoetin alfa) 72
    • Mode of Action 72
    • Approvals 72
    • Competition within the Marketplace 72
    • Patents 73
    • Market Outlook 73
    • Biosimilars in Development 74
  • Lovenox/Clexane (enoxaparin) 75
    • Mode of Action 75
    • Approvals 75
    • Competition within the Marketplace 75
    • Patents 75
    • Market Outlook 75
    • Generic Company Activity 76
      • Court of Appeals decision in enoxaparin suit 77

IMMUNOLOGY 78

  • MULTIPLE SCLEROSIS 78
    • Copaxone (glatiramer acetate) 80
      • Mode of Action 80
      • Approvals 80
      • Competition within the Marketplace 80
      • Patents 81
      • Market Outlook 81
      • Generics in Development 82
        • Sandoz and Momenta 83
        • Mylan and Natco Pharma 83
    • Avonex (interferon beta-1a) 84
      • Mode of Action 84
      • Approvals 84
      • Competition within the Marketplace 84
      • Patents 85
      • Market Outlook 85
    • Rebif (interferon beta-1a) 87
      • Mode of Action 87
      • Approvals 87
      • Competition within the Marketplace 87
      • Market Outlook 87
    • Betaferon/Betaseron & Extavia (interferon beta-1b) 89
      • Mode of Action 89
      • Approvals 89
      • Competition within the Marketplace 89
      • Patents 89
      • Market Outlook 89
      • Biosimilar Interferon Beta 90
  • RHEUMATOID ARTHRITIS 92
    • Enbrel (etanercept) 93
      • Mode of Action 93
      • Approvals 93
      • Competition within the Marketplace 93
      • Patents 93
      • Market Outlook 94
      • Biosimilar Etanercept 95
    • Humira (adalimumab) 97
      • Mode of Action 97
      • Approvals 97
      • Competition within the Marketplace 97
      • Patents 97
      • Market Outlook 98
      • Biosimilar Adalimumab 99
    • Remicade (infliximab) 100
      • Mode of Action 100
      • Approvals 100
      • Competition within the Marketplace 100
      • Patents 100
      • Market Outlook 101
      • Biosimilar Infliximab 103

INFECTION 104

  • Cubicin (daptomycin) 104
    • Mode of Action 104
    • Approvals 104
    • Competition within the Marketplace 105
    • Patents 105
    • Market Outlook 105
    • Generic Company Activity 106
  • Invanz (ertapenem) 108
    • Mode of Action 108
    • Approvals 108
    • Competition within the Marketplace 108
    • Patents 108
    • Market Outlook 109
    • Generic Company Activity 110
  • Tygacil (tygecycline) 111
    • Mode of Action 111
    • Approvals 111
    • Competition within the Marketplace 111
    • Patents 112
    • Market Outlook 112
    • Generic Company Activity 113
  • Synagis (palivizumab) 114
    • Mode of Action 114
    • Approvals 114
    • Competition within the Marketplace 114
    • Patents 114
    • Market Outlook 114
    • Biosimilar Development 115
  • PegIntron (peginterferon alfa-2b) 116
    • Mode of Action 116
    • Approvals 116
    • Competition within the Marketplace 116
    • Patents 116
    • Market Outlook 117
  • Pegasys (pegylated-40K interferon alfa-2a) 118
    • Mode of Action 118
    • Approvals 118
    • Competition within the Marketplace 118
    • Patents 118
    • Market Outlook 119
  • Biosimilar Interferon Alfa 120

MAJOR COMPETITORS 122

  • ACTAVIS 127
    • Products 127
    • Major Developments 128
      • Acquisitions & Agreements 128
        • Actavis completes acquisition of Warner Chilcott 128
      • Litigation 128
        • Generic Diprivan patent challenge 128
        • Generic Velcade patent challenge 128
  • AKORN 129
    • Products 129
    • Acquisitions & Agreements 129
      • Akorn completes acquisition of Kilitch Drugs (India) 129
      • Akorn acquires injectables from Lundbeck 129
  • AMERICAN REGENT 130
    • Products 130
  • AMPHASTAR PHARMACEUTICALS 132
    • Products 132
  • APOTEX 133
    • Products 133
    • Agreements 133
      • Stada Arzneimittel in-licenses Grastofil 133
  • AUROBINDO PHARMA 134
    • Products 134
  • CLARIS LIFESCIENCES 135
    • Products 135
    • Recent Developments 135
      • Claris Lifesciences completes transfer of its Infusion Business for India and Emerging Markets
      • to the joint venture with Otsuka Pharmaceutical and Mitsui 135
      • Claris Lifesciences to sell on its own in the US 136
  • DR REDDY'S LABORATORIES 137
    • Products 137
  • FRESENIUS KABI 138
    • Products 138
    • Product recalls 139
      • Fresenius Kabi recalls Benztropine Mesylate injection 139
      • Fresenius Kabi recalls single lot of magnesium sulphate 139
    • Acquisitions 139
      • APP acquires three products from Nexus 139
    • Agreements 139
      • Fresenius Kabi begins joint venture on IV generics in Indonesia 139
      • APP and Teva enter gemcitabine agreement 140
    • Litigation 140
      • APP settles with the Medicines Company on Angiomax patent litigation 140
  • HIKMA PHARMACEUTICALS 141
    • Products 141
    • Acquisitions & Agreements 142
      • Commercial supply contract with Unilife Medical Solutions 142
      • Hikma enters Ethiopian pharmaceutical market through joint venture with MIDROC Group 142
  • HOSPIRA 143
    • Products 143
      • Biosimilars 143
    • Acquisitions & Agreements 144
      • Hospira signs agreement with Q Core Medical for International distribution of Sapphire Infusion System 144
      • Hospira acquires API manufacturing and R&D facilities from Orchid 144
    • Litigation 145
      • Cubicin patent infringement lawsuit 145
  • MYLAN 146
    • Products 146
    • Acquisitions 146
      • Mylan's acquires Agila from Strides Arcolab 146
    • Litigation 148
      • Mylan and Teva settle Copaxone patent litigation 148
  • SAGENT PHARMACEUTICALS 149
    • Products 149
      • Product recalls 150
        • Sagent Pharmaceuticals announces expanded recall of vecuronium bromide 150
      • Acquisitions and Agreements 151
        • Sagent Pharmaceuticals announces agreement to acquire remaining 50% interest in Chinese
        • manufacturing joint venture 151
        • Sagent announces amendment to supply agreement with Actavis 151
  • SANDOZ 152
    • Products 152
      • Biosimilars 153
        • Marketed biosimilar products 153
        • Etanercept Phase III trial 153
    • Litigation 154
      • Sandoz's generic Copaxone does not infringe Teva's patent 154
  • STRIDES ARCOLAB 155
    • Products 155
      • Agreements 157
      • Pfenex and Agila Biotech in joint venture to develop biosimilars for global market 157
      • Sale of Agila Specialties division to Mylan 157
      • Strides and Eli Lilly strategic partnership to deliver generic cancer medicines in emerging markets 157
      • Strides Arcolab sells generic pharmaceutical operations in Australia and Southeast Asia to Watson
      • Pharmaceuticals 157
  • SUN PHARMA 158
    • Products 158
    • Acquisitions & Agreements 159
      • Sun Pharma and Intrexon joint venture to develop new class of therapeutics for Ocular Diseases 159
      • Sun Pharma and Taro announce termination of proposed merger 159
      • Sun Pharma to acquire URL Generic from Takeda 159
  • TEVA PHARMACEUTICAL INDUSTRIES 160
    • Products 160
      • Biopharmaceuticals and Biosimilars 161
    • Litigation 162
      • Teva and Mylan settle patent dispute 162
    • Agreements 162
      • Teva and Lonza discontinue biologics joint venture 162
      • Teva terminates agreements with CureTech 162
      • Teva enters agreement with Handok 162
  • WOCKHARDT 163
    • Products 163

Appendix: FDA ANDA Approvals 164

Sources 171

Index 172

List of Tables

  • Global Sales of Injectable Pharmaceuticals, 2011-2012 (US$ Million) 4
  • US Patent Expiry for Leading Injectable Drugs 6
  • Paragraph IV Certifications, January 2009-June 2013 7
  • Faslodex US Patents 9
  • Faslodex Sales, 2008-2012 (US$ Million) 10
  • Zoladex US Patents 12
  • Zoladex Sales, 2008-2012 (US$ Million) 12
  • Eloxatin US Patents 16
  • Eloxatin Sales, 2008-2012 (EUR & US$ Million) 16
  • FDA Approvals for Generic Oxaliplatin 18
  • Taxotere Sales, 2008-2012 (EUR & US$ Million) 20
  • EU Marketing Authorisations for Generic Docetaxel 21
  • Abraxane US Patents 23
  • Abraxane Sales, 2008-2012 (US$ Million) 23
  • Alimta US Patents 26
  • Alimta Sales 2008-2012 (US$ Million) 26
  • Velcade US Patents 29
  • Velcade Sales by Company, 2008-2012 (US$ Million) 29
  • Rituxan/MabThera Sales, 2008-2012 (CHF & US$ Million) 33
  • Herceptin US Patents 36
  • Herceptin Sales, 2008-2012 (CHF & US$ Million) 36
  • Avastin Sales, 2008-2012 (CHF & US$ Million) 40
  • Erbitux Sales by Company, 2008-2012 (EUR & US$ Million) 42
  • Five-year Sales of Leading G-CSF Brands (US$ Million) 44
  • Filgrastim US Patents 45
  • Neupogen Sales, 2008-2012 (US$ Million) 46
  • EU Marketing Authorisations for Biosimilar Filgrastim 47
  • Neulasta Patents 50
  • Neulasta Sales, 2008-2012 (US$ Million) 50
  • Five-Year Sales of Leading Insulin Brands (US$ Million) 52
  • Humulin Sales, 2008-2012 (US$ Million) 53
  • Humalog US Patents 55
  • Humalog Sales, 2008-2012 (US$ Million) 56
  • Lantus US Patents 57
  • Lantus Sales, 2008-2012 (EUR & US$ Million) 58
  • Apidra US Patents 59
  • Apidra Sales, 2008-2012 (EUR & US$ Million) 60
  • Levemir US Patents 61
  • Levemir Sales, 2008-2012 (DKK & US$ Million) 62
  • NovoRapid & NovoMix US Patents 64
  • NovoMix & NovoRapid Sales, 2008-2012 (DKK & US$ Million) 64
  • Epogen US Patents 68
  • Epogen/Eprex/Procrit Sales, 2008-2012 (US$ Million) 69
  • Biosimilar Eprex Approved in the EU 70
  • Aranesp US & EU Patents 73
  • Aranesp Sales, 2008-2012 (US$ Million) 73
  • Lovenox/Clexane Sales, 2008-2012 (EUR & US$ Million) 76
  • FDA ANDA Approvals for Mitoxantrone 79
  • Copaxone US Patents 81
  • Copaxone Sales by Company, 2008-2012 (US$ Million) 82
  • Avonex US Patents 85
  • Avonex Sales 2008-2012 (US$ Million) 85
  • Rebif Sales, 2008-2012 (EUR & US$ Million) 88
  • Betaferon/Betaseron & Extavia Sales, 2008-2012 (EUR & US$ Million) 90
  • Biosimilar Interferon Beta in Emerging Markets 91
  • Enbrel US Patents 94
  • Enbrel Sales by Company, 2008-2012 (US$ Million) 94
  • Humira US Patents 97
  • Humira Sales by Company, 2008-2012 (US$ Million) 98
  • Remicade US Patents 100
  • Remicade Sales by Company, 2008-2012 (US$ Million) 101
  • Cubicin US Patents 105
  • Cubicin Sales, 2008-2012 (US$ Million) 106
  • Invanz US Patents 109
  • Invanz Sales, 2008-2012 (US$ Million) 109
  • Tygacil US Patents 112
  • Tygacil Sales, 2008-2012 (US$ Million) 112
  • Synagis US Patents 114
  • Synagis Sales, 2008-2012 (US$ Million) 115
  • PegIntron US Patents 116
  • PegIntron Sales, 2008-2012 (US$ Million) 117
  • Pegasys US Patent 119
  • Pegasys Sales, 2008-2012 (CHF & US$ Million) 119
  • Biosimilar Interferon Alfa in Emerging Markets 120
  • Actavis ANDA Approvals for Injectables, 2010-2013 127
  • Akorn ANDA Approvals for Injectables, 2010-2013 129
  • PharmaForce ANDA Approvals for Injectables, 2010-2013 130
  • Luitpold Pharmaceuticals ANDA Approvals for Injectables, 2010-2013 131
  • Amphastar ANDA Approval, 2011 132
  • Aurobindo ANDA Approvals for Injectables, 2010-2013 134
  • Claris Lifesciences FDA ANDA Approvals, 2010-2013 135
  • Dr Reddy's ANDA Approvals, 2010-2013 137
  • APP ANDA Approvals, 2010-2013 138
  • Fresenius Kabi ANDA Approvals, 2010-2013 139
  • Hikma ANDA Approvals for Injectables, 2010-2013 141
  • Hospira ANDA Approvals, 2010-2013 143
  • Mylan Institutional ANDA Approvals, 2010-2013 146
  • Sagent Strides ANDA Approvals, 2010-2013 149
  • Sagent Agila ANDA Approvals, 2011-2012 150
  • Sagent ANDA Approvals, 2010-2013 150
  • Sandoz ANDA Approvals for Injectables, 2010-2013 152
  • Sagent Strides ANDA Approvals, 2010-2013 155
  • Onco Therapies ANDA Approvals, 2011-2013 156
  • Sun Pharma ANDA Approvals for Injectables, 2010-2013 158
  • Teva ANDA Approvals for Injectables, 2010-2013 160
  • PharmaChemie ANDA Approvals for Injectables, 2010-2012 160
  • Wockhardt ANDA Approvals for Injectables, 2011 163
  • FDA ANDA Approvals, January 2011-October 2013 164
  • List of Figures
  • Faslodex Sales, 2008-2018 (US$ Million) 10
  • Zoladex Sales, 2008-2018 13
  • Eloxatin Sales, 2008-2018 (US$ Million) 17
  • Taxotere Sales, 2008-2018 (US$ Million) 20
  • Abraxane Sales, 2008-2018 (US$ Million) 24
  • Alimta Sales 2008-2018 (US$ Million) 27
  • Velcade Sales, 2008-2017 (US$ Million) 30
  • Rituxan/MabThera Sales, 2008-2018 (US$ Million) 33
  • Herceptin Sales, 2008-2018 (US$ Million) 37
  • Avastin Sales, 2008-2018 (US$ Million) 40
  • Erbitux Sales, 2008-2018 (US$ Million) 43
  • Neupogen Sales, 2008-2018 (US$ Million) 46
  • Neulasta Sales, 2008-2018 (US$ Million) 50
  • Humulin Sales, 2008-2018 (US$ Million) 54
  • Humalog Sales, 2008-2018 (US$ Million) 56
  • Lantus Sales, 2008-2018 (US$ Million) 58
  • Apidra Sales, 2008-2018 (US$ Million) 60
  • Levemir Sales, 2008-2018 (US$ Million) 62
  • NovoMix & NovoRapid Sales, 2008-2018 (US$ Million) 65
  • Epogen/Eprex/Procrit Sales, 2008-2018 (US$ Million) 69
  • Aranesp Sales, 2008-2018 (US$ Million) 74
  • Lovenox/Clexane Sales, 2008-2018 (US$ Million) 76
  • Copaxone Sales, 2008-2018 82
  • Avonex Sales, 2008-2018 (US$ Million) 86
  • Rebif Sales, 2008-2018 (US$ Million) 88
  • Betaferon/Betaseron Sales, 2008-2018 (US$ Million) 90
  • Enbrel Sales, 2008-2012 (US$ Million) 95
  • Humira Sales, 2008-2018 (US$ Million) 98
  • Remicade Sales, 2008-2018 (US$ Million) 102
  • Cubicin Sales, 2008-2018 (US$ Million) 106
  • Invanz Sales, 2008-2018 (US$ Million) 109
  • Tygacil Sales, 2008-2018 (US$ Million) 113
  • Synagis Sales, 2008-2018 (US$ Million) 115
  • PegIntron Sales, 2008-2018 (US$ Million) 117
  • Pegasys Sales, 2008-2018 (US$ Million) 119
  • FDA ANDA Approvals by Company, January 2010-October 2013 124
  • FDA ANDA Approvals by Company, January 2008-October 2013 125
  • Injectable Generics Market by Company, 2012 (Volume %) 126
Back to Top